DHHS Adult ARV Guidelines
Interaction Color Code
Clinical Bottom Line
Minimal data to guide interaction: weigh risks and benefits of using this combination
Drug 1
Drug 2
Mechanism
Inhibition of CYP3A4 by lenacapavir
Clinical Effects
Potential increased risk of corticosteroid adverse effects (e.g. Cushing's syndrome and adrenal supression).
Management
If coadministering, initiate lowest starting dose and titrate to clinical effect. Monitor for adverse effects such as adrenal insufficiency and Cushing's syndrome.
Info Source
